A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients
← catalyst calendarNCT06133010 · readout in 179 d
Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →.
Phase
Phase 2
Status
Withdrawn
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Trial was cancelled by Sponsor
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-08 | actual | When the study began enrolling |
| Primary completion | 2027-02-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-14 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-03-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cytomegalovirus Infection
Interventions
- Biological: mRNA-1647
- Biological: Placebo
Primary outcomes
what the primary-completion date above is the date OFPost-transplant: Time to the First Occurrence of a Clinically Significant Cytomegalovirus Infection (CS-CMVi) In Seropositive Participants
measured Day 373 through Day 466
Number of Participants With Solicited Local and Systemic Adverse Reactions
measured Up to Day 64 (7 days after the last study injection)
Number of Participants With Unsolicited Adverse Events
measured Up to Day 87 (28 days after the last study injection)
Number of Participants With Medically Attended Adverse Events
measured Up to Day 237 (6 months after the last study injection)
Number of Participants With Serious Adverse Events
measured Day 1 through Day 542
Number of Participants With Adverse Events of Special Interest
measured Day 1 through Day 542
Number of Participants With Adverse Events Leading to Discontinuation
measured Day 1 through Day 542
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed